States have committed and assumed obligations to address multiple and intersecting forms of discrimination against refugees, internally displaced persons, asylum seekers, returnees and stateless persons. The Global Compact on Refugees places ending discrimination of any kind based on the grounds of ...race, colour, sex, language, religion, political or other opinion, national or social origin, property, birth, disability, age, or other status at the centre of action to prevent displacement and to ensure peaceful coexistence between refugee and host communities. Narratives about cultural diversity and inclusion are important, but there is also a pressing need in many societies for conversations and action to address racism, racial discrimination, xenophobia and related intolerance.
more
This was a Phase 3, multi-center, randomized, open-label, parallel-group, active control study where 273 male and female patients with first stage Trypanosoma brucei gambiense HAT were treated at six sites: one trypanosomiasis reference center in Angola, one hospital in South Sudan, and four hospita...ls in the Democratic Republic of the Congo between August 2005 and September 2009 to support the registration of pafuramidine for treatment of first stage HAT in collaboration with the United States Food and Drug Administration. Patients were treated with either 100 mg of pafuramidine orally twice a day for 10 days or 4 mg/kg pentamidine intramuscularly once daily for 7 days to assess the efficacy and safety of pafuramidine versus pentamidine. Pregnant and lactating women as well as adolescents were included.
more
Female Genital Schistosomiasis (FGS) is a gynaecological disease caused by Schistosoma haematobium, a parasitic worm that is acquired by skin contact with freshwater contaminated by schistosome cerceriae. Communities in which the infection is most endemic have limited access to clean water and healt...hcare services. Up to 150 million adolescent girls and women are estimated to be at risk of FGS and about 16–56 milion womens are living with FGS, with the majority of these in sub-Saharan Africa. The variability of these estimates points to the fact that this neglected tropical disease is not well studied and frequently not prioritized by local, regional, and global health policy makers.
more
Les progrès remarquables réalisés dans la lutte contre la forme à T. b. gambiense reposent sur le dépistage et le traitement curatif, une stratégie qui interrompt la transmission en réduisant le réservoir de parasites chez l’être humain. Parfois, cette
approche a été combinée avec des... activités de lutte antivectorielle. L’objet de ces lignes directrices est donc de la plus haute importance pour la poursuite des progrès en vue de l’élimination de la THA.
more
Arsenical monotherapies were previously very successful for treating human African trypanosomiasis (HAT).
Melarsoprol resistance emerged as early as the 1970s and was widespread by the late 1990s.
Melarsoprol resistance represents the only example of widespread drug resistance in HAT patients wher...e the genetic mechanism has been established.
The current goal of elimination of HAT as a public health problem by 2020 may be undermined by the emergence and spread of resistance to current or new drugs.
Insights into potential resistance mechanisms for current and new drugs will facilitate predictions of the likelihood of resistance and will also facilitate rational approaches to minimizing, monitoring, and tackling the future emergence of resistance.
more
More countries eliminate human African trypanosomiasis as a public health problem: Benin and Uganda (gambiense form) and Rwanda (rhodesiense form)
Human African trypanosomiasis (HAT), or sleeping sickness, transmitted by tsetse flies in sub-Saharan Africa, is a life-threatening disease that afflict...s poor rural populations. It is caused by trypanosome parasites of 2 subspecies: Trypanosoma brucei gambiense in West and Central Africa, and T. b. rhodesiense in East Africa.
HAT transmission can be reduced and interrupted by deploying and maintaining capacities for testing people at risk in order to detect and treat cases, and by controlling tsetse populations that are in contact with humans.
more
Sleeping sickness is controlled by case detection and treatment but this often only reaches less than 75% of the population. Vector control is capable of completely interrupting HAT transmission but is not used because of expense. We conducted a full scale field trial of a refined vector control tec...hnology. From preliminary trials we determined the number of insecticidal tiny targets required to control tsetse populations by more than 90%. We then carried out a full scale, 500 km2 field trial covering two HAT foci in Northern Uganda (overall target density 5.7/km2). In 12 months tsetse populations declined by more than 90%. A mathematical model suggested that a 72% reduction in tsetse population is required to stop transmission in those settings. The Ugandan census suggests population density in the HAT foci is approximately 500 per km2. The estimated cost for a single round of active case detection (excluding treatment), covering 80% of the population, is US$433,333 (WHO figures). One year of vector control organised within country, which can completely stop HAT transmission, would cost US$42,700. The case for adding this new method of vector control to case detection and treatment is strong. We outline how such a component could be organised.
more
Chagas disease (CD) is caused by Trypanosoma cruzi. When acquired, the
disease develops in stages. For diagnosis, laboratory confirmation is required, and an extensive assessment of the patient’s health should be performed. Treatment consists of the administration of trypanocidal drugs, which may... cause severe adverse effects. The objective of our systematic review was to analyze data contained in the CD published case reports to understand the challenges that patients and clinicians face worldwide.
more
In May the Sixty-sixth World Health Assembly adopted resolution WHA66.12 (1) on 17 neglected tropical diseases (NTDs). Among other measures, the resolution urges Member States to:
• ensure country ownership of prevention, control, elimination and eradication programmes;
• expand and implemen...t interventions and advocate for predictable, long-term international financing for activities related to control and capacity strengthening;
• integrate control programmes into primary health-care services and existing programmes;
• ensure optimal programme management and implementation;
• achieve and maintain universal access to interventions and reach the targets of the roadmap.
more
Countries are making progress toward the global goal of 95% of people living with HIV knowing their status by 2025. However, considerable gaps remain in achieving these goals globally. Men in high HIV burden settings and men from key populations in all settings are consistently less likely to know t...heir HIV status than women. Globally, 78% of men ages 15 years and older who are living with HIV are aware of their HIV status, compared with 86% of women with HIV of these ages.
Offering HIV testing services, including HIV self-testing, at formal and informal workplaces has emerged as an effective, acceptable and feasible approach for reaching men. A 2018 World Health Organization (WHO) and International Labour Organization (ILO) policy brief provides key guiding principles for HIVST implementation at workplaces. Building on the 2018 policy brief, this brief captures early experience with HIVST implementation at workplaces and discusses emerging approaches of sustainable financing that can be adapted for HIV self-testing at workplaces.
The primary audiences for this policy brief are ministries of health and labour, national HIV programmes, employers’ organizations, workers’ organizations (labour unions), enterprises, implementing partners, including civil society organizations, and health insurance agencies.
more
Les pays progressent vers la réalisation de l’objectif mondial tendant à ce que, d’ici 2025, 95 pour cent des personnes qui vivent avec le VIH connaissent leur statut sérologique. Cependant, en 2020, on estimait encore à 6 millions le nombre de personnes séropositives non diagnostiquées da...ns le monde. Les hommes vivant dans des lieux où la prévalence du VIH est élevée et les hommes appartenant aux populations clés, tous lieux confondus, ont moins de chances de connaître leur séropositivité que les femmes. Ainsi, au niveau mondial, 78 pour cent des hommes de plus de 15 ans connaissent leur statut sérologique, contre 86 pour cent chez les femmes de cette même tranche d’âge.
more
Les pays progressent vers la réalisation de l’objectif mondial tendant à ce que, d’ici 2025, 95 pour cent des personnes qui vivent avec le VIH connaissent leur statut sérologique. Cependant, en 2020, on estimait encore à 6 millions le nombre de personnes séropositives non diagnostiquées da...ns le monde. Les hommes vivant dans des lieux où la prévalence du VIH est élevée et les hommes appartenant aux populations clés, tous lieux confondus, ont moins de chances de connaître leur séropositivité que les femmes. Ainsi, au niveau mondial, 78 pour cent des hommes de plus de 15 ans connaissent leur statut sérologique, contre 86 pour cent chez les femmes de cette même tranche d’âge.
more
More than one million people each year become infected by parasites that cause the disease cutaneous leishmaniasis (CL). This disease manifests as one or more skin lesions or ulcers that are slow to heal with variable response rates to drug treatments. Thus far, little attention has been paid to how... the cultural effects of gender shape perceptions and experiences of CL. This review aims to bring together and analyse existing studies which use qualitative data to explore these differences. These studies offered insights into our specific research questions.
more
Leishmaniasis is a spectrum of disease caused by the infection of protozoan parasite Leishmania mainly affecting the antigen presenting cell of the host. The disease is although considered as neglected tropical disease still it is not completely eradicated. Majority of the issues related to the ther...apeutic approach is due to increased cytotoxicity of the drugs, less effectiveness, high cost and occurrence of drug resistance. Therefore, recent advancement in the field of parasitology has taken into consideration of the specific arms of immunity which can be triggered with the help of natural products, synthetic molecules or parasite specific ligands which helps in the restoration of host protective immunity and recovery from the infection. Therefore, in this review, we have highlighted the recent advancement in the field of Leishmania research taken into consideration of the therapeutic perspective. We have shown that apart from therapeutic potential of the available drugs and vaccination approach, the immune-therapy are emerging as the modern regime of treatment where the effectiveness of the therapy is significantly increased and making it safer and promising.
more
Leptospirosis is an infectious disease caused by pathogenic organisms belonging to the genus Leptospira, that are transmitted directly or indirectly from animals to humans. Leptospirosis is a major direct zoonosis. Humanto-human transmission occurs only very rarely.
Chromoblastomycosis (CBM), represents one of the primary implantation mycoses caused by melanized fungi widely found in nature. It is characterized as a Neglected Tropical Disease (NTD) and mainly affects populations living in poverty with significant morbidity, including stigma and discrimination.
Several Public Health Services and general practitioners in the Netherlands observed an increase in scabies in the Netherlands. Since individual cases of scabies are not notifiable in the Netherlands, the epidemiological situation is mostly unknown. To investigate the scabies incidence in the Nether...lands, we described the epidemiology of scabies between 2011 and 2021.
more
This project aimed to reduce the risk of vector-borne infection with Chagas disease by
controlling triatomine bugs, the vectors transmitting the parasite of Chagas disease, and
establishing an epidemiological surveillance system with community participation.
Snakebite is an acute life threatening time limiting medical emergency. It is a preventable public
health hazard often faced by rural population in tropical and subtropical countries with heavy
rainfall and humid climate.
El desarrollo, desde 1991, de las Iniciativas Subregionales de Control de la Enfermedad de Chagas, y los avances de conocimiento en materia de diagnóstico y manejo de la infección/enfermedad de Chagas, llevan a la necesidad ética, y operativamente imperiosa, de estructurar el diagnóstico, atenci...ón y tratamiento de esta afección.
Una situación particularmente delicada, preocupante y alarmante, se constituye por la escasa einequitativa disponibilidad de los limitados recursos terapéuticos, actualmente disponibles, para el tratamiento etiológico de Chagas, en la mayor parte de los países endémicos de América.
En esta situación, se propone el desarrollo de la Consulta técnica regional OPS/MSF sobre organización y estructura de la atención médica del enfermo e infectado por Trypanosoma cruzi (enfermedad de Chagas), con los objetivos de:
- definir el alcance y estructura de la atención médica al paciente, tanto en diagnóstico, manejo como tratamiento;
- desarrollar modelos alternativos y optativos de atención, asimilables a las estructurassanitarias de los países;
- delinear la atención del chagásico, según su momento biológico-patológico evolutivo,dentro de los niveles de complejidad de la atención médica;
- establecer consideraciones sobre la atención pediátrica, materno-infantil, transfusional y mayor complejidad;
- definir las necesidades y alcances del diagnóstico de la enfermedad;
- establecer los alcances y facilidades que, dentro de los sistemas de atención, deben poseer estos pacientes;
- definir el panorama total de disponibilidad y accesibilidad de los pacientes al tratamiento etiológico de esta dolencia;
- proyectar conceptos y concepciones marco sobre el costo, impacto y efectividad del
desarrollo de este componente de morbilidad y atención en enfermedad de Chagas; y
- establecer las necesidades de investigación operativa y de gestión para avanzar en el
desarrollo de la atención médica a este grupo de pacientes.
Esta consulta, desarrollada en la ciudad de Montevideo, el 13 y 14 de octubre de 2005, pretende marcar la elaboración de una guía conceptual para comentarla y diseminarla en el año 2006, desde las cinco Iniciativas Intergubernamentales Subregionales de Control de Enfermedad de Chagas.
more